“While the weight loss results were impressive across the group, the cost and side effects remain important barriers for long ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Investing in stocks remains one of the best ways to accumulate capital over long periods. Companies that can last -- and thrive -- that long are rare, but let's consider two brilliant examples ...

Eli Lilly’s Global CEO David Ricks revealed that the pharma giant might manufacture its weight-loss blockbuster, Mounjaro, in ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

With approximately 101 million individuals living with diabetes, increasing access to insulin and advanced treatments is ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Dr. Jitendra Singh, a renowned endocrinologist himself, emphasized the unique metabolic challenges faced by India due to its ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.

Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this ...